Laser ablation-based one-step generation and bio-functionalization of gold nanoparticles conjugated with aptamers

Bio-conjugated nanoparticles are important analytical tools with emerging biological and medical applications. In this context in situ conjugation of nanoparticles with biomolecules via laser ablation in aqueous media is a highly promising one step method for the production of functional nanoparticles resulting in high conjugation efficiencies.

Increased yields are required particularly considering the conjugation of cost intensive biomolecules like RNA aptamers.

Results: Using a DNA aptamer directed against streptavidin in situ conjugation results in nanoparticles with diameters of approximately 9 nm exhibiting a high surface density of aptamers (98 aptamers per nanoparticle) and a maximal conjugation efficiency of 40.3%. We have demonstrated the functionality of the aptamer-conjugated nanoparticles in three independent analytical methods including an agglomeration-based colorimetric assay and solid-phase assays proving high aptamer activity.

To demonstrate the general applicability of the in situ conjugation of gold nanoparticles with aptamers we have transferred the approach to a RNA aptamer directed against prostate specific membrane antigen (PSMA). Successful detection of PSMA in human prostate cancer tissue was achieved utilizing tissue microarrays.

Conclusions: In comparison to conventional generation of bio-conjugated gold nanoparticles by chemical synthesis and subsequent bio-functionalization, the laser ablation-based in situ conjugation allows the rapid one-step production.

Due to high conjugation efficiency and productivity in situ conjugation can be easily used for high throughput generation of gold nanoparticles conjugated with precious biomolecules like aptamers.

Author: Johanna WalterSvea PetersenFrank StahlThomas ScheperStephan Barcikowski
Credits/Source: Journal of Nanobiotechnology 2010, 8:21

Published on: 2010-08-23

Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.

Comments Page 0 of 0

There are currently 0 comments to display.

+ Add New Comment

Custom Search